|Bid||0.5360 x 100|
|Ask||0.5500 x 11800|
|Day's Range||0.5300 - 0.5884|
|52 Week Range||0.4000 - 4.9500|
|PE Ratio (TTM)||-0.31|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
In early April 2017, Atossa closed a public offering with gross proceeds to Atossa of approximately $4.4 million. The offering included 664,000 Class A Units at a public offering price of $0.75 per Class A Unit, which consisted of 664,000 shares of Common Stock and Warrants to purchase 664,000 shares of Common Stock. The offering also included 3,502 Class B Units at a public offering price of $1,000 per Class B Unit, which consisted of 3,502 shares of Series A Convertible Preferred Stock convertible into a total of 4,669,333 shares of Common Stock and Warrants to purchase 4,669,333 shares of Common Stock.
Atossa Genetics stock fell 27.5 percent after the company announced plans to raise $4.6 million in an underwritten public offering on Tuesday. The Seattle biotech company declined to comment during the stock offering period. Atossa develops drugs and medical devices that treat breast cancer and other breast conditions.
On Jan 9, 2017, Atossa (ATOS) announced that it is transferring the site of its Phase II study of fulvestrant administered with its patented microcatheters in patients with ductal carcinoma in situ or breast cancer who are scheduled for lumpectomy or mastectomy. The study was initiated at Columbia University Medical Center Breast Cancer Programs (New York) and is now being transferred to Montefiore Medical Center in New York. This move comes about as the principal investigator, Dr. Sheldon M. Feldman, M.D., has relocated to Montefiore and is now Chief, Division of Breast Surgery & Breast Surgical Oncology, Director, Breast Cancer Services, and Professor, Department of Surgery, at the Montefiore Medical Center, The University Hospital for the Albert Einstein College of Medicine, Montefiore Einstein Center for Cancer Care.